Pfizer stuns Wall Street with booming Q3 earnings and new guidance boost
Pfizer Inc. delivered a financial jolt in its third quarter of 2024, surpassing Wall Street’s expectations and raising its annual revenue and earnings guidance for ... Read More
Pfizer gets PAXLOVID FDA approval for COVID-19 in high-risk adults
Pfizer has obtained approval for PAXLOVID, an oral combination therapy of nirmatrelvir tablets and ritonavir tablets, from the US Food and Drug Administration (FDA) to ... Read More
Pfizer to acquire cancer drugmaker Seagen for $43bn in cash
American pharmaceutical and biotechnology company Pfizer has agreed to acquire cancer drugmaker Seagen (formerly Seattle Genetics) for $229 per share or $43 billion in cash, ... Read More
FDA grants EUA for Omicron-adapted Covid-19 vaccine for children below five
Pfizer and BioNTech have received the US Food and Drug Administration (FDA) emergency use authorization (EUA) for their Omicron BA.4/BA.5-adapted bivalent Covid-19 vaccine for children ... Read More
Pfizer to acquire Oxbryta developer Global Blood Therapeutics for $5.4bn
Pfizer has agreed to acquire Global Blood Therapeutics (GBT), a publicly-listed American biopharma company, in a deal worth around $5.4 billion with an aim to ... Read More
Pfizer and BioNTech’s COVID-19 vaccine secures FDA emergency use authorization
In a groundbreaking move, Pfizer and BioNTech have received emergency use authorization (EUA) from the US Food and Drug Administration (FDA) for their COVID-19 vaccine, ... Read More
UK grants emergency authorization for Pfizer and BioNTech’s BNT162b2 Covid-19 vaccine
The UK Medicines and Healthcare Products Regulatory Agency (MHRA) has granted emergency use authorization (EUA) for the BNT162b2 Covid-19 vaccine candidate, developed by Pfizer and ... Read More
BNT162b2 Covid-19 vaccine candidate more than 90% effective in phase 3 trial, say Pfizer and BioNTech
Pfizer and BioNTech announced that the BNT162b2 mRNA-based vaccine candidate has been shown to be more than 90% effective in the prevention of Covid-19 in ... Read More
Pfizer to manufacture Gilead’s Covid-19 drug candidate remdesivir
Pfizer has signed a multi-year agreement with Gilead Sciences to manufacture and supply the latter's investigational antiviral remdesivir for the treatment of Covid-19. Under the ... Read More